- Conditions
- Mitochondrial Diseases
- Interventions
- Napazimone
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Akron, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–15
of 15
matching trials from the live ClinicalTrials.gov search.
- Conditions
- APDS
- Interventions
- Leniolisib
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Standford, California • Atlanta, Georgia + 1 more
- Conditions
- Hereditary Angioedema
- Interventions
- rhC1INH
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Primary Immunodeficiency Disorders (PIDs)
- Interventions
- Leniolisib
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Common Variable Immunodeficiency (CVID)
- Interventions
- Leniolisib
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Bethesda, Maryland • Burlington, Massachusetts + 2 more
- Conditions
- Activated PI3Kdelta Syndrome (APDS); PASLI Disease
- Interventions
- CDZ173
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hereditary Angioedema
- Interventions
- Recombinant human C1 inhibitor, Placebo
- Biological · Other
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 4
- States / cities
- Tampa, Florida • St Louis, Missouri • Lake Oswego, Oregon
- Conditions
- APDS
- Interventions
- Leniolisib
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 1 Year to 6 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Bethesda, Maryland • Shaker Heights, Ohio + 1 more
- Conditions
- PIDs Linked to PI3K
- Interventions
- Leniolisib
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Burlington, Massachusetts • New York, New York
- Conditions
- Hereditary Angioedema
- Interventions
- rhC1INH, Placebo (Saline)
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more
- Conditions
- Primary Mitochondrial Disease
- Interventions
- KL1333, Placebo
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 20
- States / cities
- Orange, California • San Diego, California • San Francisco, California + 15 more
- Conditions
- Graft Rejection, Kidney Transplantation
- Interventions
- plasmapheresis and IVIG, recombinant C1 inhibitor
- Procedure · Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Kidney Failure
- Interventions
- rhC1INH, Saline Solution
- Drug · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Confirmed Coronavirus Disease
- Interventions
- Ruconest
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 4
- States / cities
- Marlton, New Jersey • Mount Holly, New Jersey • Ridgewood, New Jersey + 1 more
- Conditions
- Hereditary Angioedema
- Interventions
- rhC1INH
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 2 Years to 13 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon